Disruption of either BDNF or endocannabinoid signaling is associated with an overlapping set of neurologic and psychiatric diseases, and both systems are currently major targets for the development of novel therapeutics, particularly in relation to depression, anxiety, autism, and schizophrenia. The gene discussed is BDNF; the disease is schizophrenia.